Cargando…

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients

PURPOSE: The aim of this study was to evaluate the risk of immune-related adverse events (irAEs) among cancer patients receiving nivolumab-plus-ipilimumab therapy and nivolumab monotherapy. PATIENTS AND METHODS: PubMed and Web of Science were searched for related studies from inception to June 2018....

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Shi, Khanal, Samrat, Zhang, Haijun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362938/ https://www.ncbi.nlm.nih.gov/pubmed/30774357 http://dx.doi.org/10.2147/TCRM.S193338

Ejemplares similares

Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022)

Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma
por: Gautron Moura, Bianca, et al.
Publicado: (2022)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

SUN-414 Immune Related Adverse Events: Isolated ACTH Deficiency with Nivolumab/Ipilimumab Combination Therapy
por: Magdaleno, Angela, et al.
Publicado: (2019)

Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy—Review of the Literature and Future Outlook
por: Möhn, Nora, et al.
Publicado: (2019)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy
por: Suozzi, Kathleen C., et al.
Publicado: (2016)

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
por: Shitara, Kohei, et al.
Publicado: (2022)

Risk of Adverse Events in Cancer Patients Receiving Nivolumab With Ipilimumab: A Meta-Analysis
por: Zhao, Xin, et al.
Publicado: (2022)

Ipilimumab/nivolumab: Immune-related pneumonitis: 2 case reports
Publicado: (2020)

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
por: Janjigian, Yelena Y., et al.
Publicado: (2018)

Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis
por: Yang, Yi, et al.
Publicado: (2020)

Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma: A Meta-Analysis
por: Serritella, Anthony V., et al.
Publicado: (2023)

Real-World Incidence of Immune-Related Adverse Events Associated with Nivolumab Plus Ipilimumab in Patients with Advanced Renal Cell Carcinoma: A Retrospective Observational Study
por: Washino, Satoshi, et al.
Publicado: (2021)

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
por: Glutsch, Valerie, et al.
Publicado: (2021)

The best dosage of nivolumab plus ipilimumab combination for melanoma brain metastases
por: Fukumoto, Takeshi, et al.
Publicado: (2022)

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: Nivolumab-related serious/fatal adverse events
por: Zhao, Bin, et al.
Publicado: (2018)

Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies
por: Gunawan, Florence, et al.
Publicado: (2018)

Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date
por: Remon, Jordi, et al.
Publicado: (2019)

Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy
por: Yoshida, Saaya, et al.
Publicado: (2019)

Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma
por: Numakura, Kazuyuki, et al.
Publicado: (2023)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

Severe eosinophilia and subsequent dermatologic immune‐related adverse event with squamous cell carcinoma antigen elevation induced by nivolumab and ipilimumab
por: Matsumoto, Takeshi, et al.
Publicado: (2022)

Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data
por: Soldatos, Theodoros G., et al.
Publicado: (2018)

Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis
por: Almutairi, Abdulaali R., et al.
Publicado: (2020)

Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report
por: Miyauchi, Yasuyuki, et al.
Publicado: (2021)

Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
por: Reuss, Joshua E, et al.
Publicado: (2020)

Nivolumab plus ipilimumab: a potential regimen to rewrite treatment guidelines for ESCC
por: Luo, Yuejun, et al.
Publicado: (2022)

Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma
por: Pedersen, Jesper Geert, et al.
Publicado: (2022)

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
por: Wu, Bin, et al.
Publicado: (2018)

Severe Demyelinating Neuropathy in an Advanced Melanoma Patient Treated with Nivolumab plus Ipilimumab Combined Therapy
por: Kambayashi, Yumi, et al.
Publicado: (2020)

Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma
por: Khushalani, Nikhil I, et al.
Publicado: (2022)

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
por: Marchetti, Paolo, et al.
Publicado: (2020)

Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review
por: Nakamura, Hajime, et al.
Publicado: (2023)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
por: Nishimura, Yoshito, et al.
Publicado: (2018)

Ipilimumab/nivolumab: Diffuse pneumonitis: case report
Publicado: (2020)

Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma
por: Towner, Mary, et al.
Publicado: (2022)

Development of Nivolumab/Ipilimumab-Associated Autoimmune Nephritis during Steroid Therapy
por: Gebauer, Ellen, et al.
Publicado: (2021)

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
por: Tan, Irena, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_26u2bqhb6dl9gkffpri2i15c4e